abstract |
The present invention relates to improved filovirus vaccines and related products, methods and uses, including recombinant modified vaccinia virus Ankara (MVA) vaccines against filovirus infections. In particular, the present invention relates to engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding the antigenic determinant of Marburg virus (MARV) or Ebola virus glycoprotein. In particular, the present invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to, for example, MVA and genetically engineered (recombinant) FPV products, methods and uses suitable for eliciting a protective immune response in a subject, and a prime-boost regimen. |